Bulk Drug Market Scope
The bulk drug, also known as an active pharmaceutical ingredient (API), are active chemical substances in powder form, the main ingredient in pharmaceuticals – chemicals having therapeutic value, used for the production of pharmaceutical formulations. Major bulk drugs include antibiotics, sulpha drugs, vitamins, steroids, and analgesics. Increasing investment in research and development by major market players provides the growth in the bulk drug market globally.
According to AMA, the Global Bulk Drug market is expected to see growth rate of 7.59%
The global bilk drugs market is highly competitive and diversified due to the presence of a large number of regional and international providers across the globe. These providers are progressively focusing on the production of drugs that have a higher quality to meet the customer’s expectations. The growing R&D in drugs by manufacturers is supplementing the market growth. Research Analyst at AMA estimates that United States and China Players will contribute to the maximum growth of Global Bulk Drug market throughout the predicted period.
Teva Pharmaceutical Industries (Israel), Novartis (Switzerland), Pfizer (United States), Johnson & Johnson (United States), Mylan N.V. (United States), North China Pharmaceutical Group (China), Dr. Reddy's Laboratories (India), Roche Holding AG (Switzerland), Aurobindo pharma (India), Sun Pharmaceutical Industries Ltd. (India), Boehringer Ingelheim GmbH (Germany), Bayer (Germany), BASF (Germany), Zhejiang Medicine (China), Biocon Limited (India) and Hisun Pharmacy (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Cambrex Corporation (United States), Shandong Xinhua Pharmaceutical (China), Huahai Pharmaceutical (China) and Haerbin Pharmaceutical Group (China).
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Segmentation Overview
The study have segmented the market of Global Bulk Drug market by Type (Branded Prescription Drugs, Over-The-Counter Drugs and Generic Prescription Drugs), by Application (Pharmaceutical and Healthcare) and Region with country level break-up.
On the basis of geography, the market of Bulk Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In October 2018, Dr. Reddy’s Laboratories entered into a definitive agreement for the sale of its bulk drugs (active pharmaceutical ingredients) manufacturing unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd, an emerging generics pharmaceutical company. This acquisition represents a unique opportunity to further strengthen Therapiva’s position as a premier supplier of APIs and In November 2019, Novartis AG acquired Medicines Co. and its promising heart drug for USD 9.7 billion, the latest move in the Swiss drugmaker’s push to amass novel treatments for complex conditions.
Market Trend
- Increasing CDMOs Manufacturing Footprint in Asian Countries
- Surging Demand for Cell and Gene Therapies
- Trend for Developing Generic Drugs
Market Drivers
- The Growth in Investments Research and Development in Pharmaceutical
- Increasing Outsourcing of Clinical Trials to Developing Countries
- Rising Cost Pressures and Increasing Production Outsourcing
- Growing Demand From Biopharmaceutical Companies
Opportunities
- Increasing Investments in Advanced Manufacturing Technologies By CDMOs
- Manufacturers are Focusing on the Development of Specialty Medicines
- Government’s Support for Bulk Drugs Providing Liberalized Foreign Direct Investment (FDI) in the Pharma sector
Restraints
- Unfavourable Drug Price Control Policies Across Various Countries
- Penetration of Counterfeit Drugs
Challenges
- Introduction of Serialization
- Changing Trade Policies Between Countries
- Coping with Changing Disease Profile
Analyst View
The heightened competition among the bulk drug producers especially in Europe and the United States have boosted the market demand for the bulk drug.
Key Target Audience
Bulk Drug Manufacturing Companies, Raw Material Suppliers, Government Regulatory Bodies, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Technology Providers, End Users and Others